Clinical Trial Update: Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated how long anti-HBs antibodies persist in uraemic patients vaccinated with Henogen's HBV vaccine, Fendrix. The study status is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Fendrix

Snippet

Sponsor: Henogen | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED